Day One Biopharmaceuticals (DAWN) Other Gross PP&E Adjustments (2022 - 2025)
Day One Biopharmaceuticals (DAWN) has disclosed Other Gross PP&E Adjustments for 4 consecutive years, with -$14.0 million as the latest value for Q4 2025.
- For Q4 2025, Other Gross PP&E Adjustments fell 24.07% year-over-year to -$14.0 million; the TTM value through Dec 2025 reached -$14.0 million, down 24.07%, while the annual FY2025 figure was -$14.0 million, 24.07% down from the prior year.
- Other Gross PP&E Adjustments was -$14.0 million for Q4 2025 at Day One Biopharmaceuticals, down from -$8.2 million in the prior quarter.
- The five-year high for Other Gross PP&E Adjustments was -$1.2 million in Q1 2022, with the low at -$14.0 million in Q4 2025.
- Historically, Other Gross PP&E Adjustments has averaged -$5.3 million across 4 years, with a median of -$4.0 million in 2024.
- Biggest YoY gain for Other Gross PP&E Adjustments was 16.14% in 2023; the steepest drop was 215.46% in 2023.
- Over 4 years, Other Gross PP&E Adjustments stood at -$2.8 million in 2022, then crashed by 82.72% to -$5.1 million in 2023, then plummeted by 120.67% to -$11.3 million in 2024, then dropped by 24.07% to -$14.0 million in 2025.
- Per Business Quant database, its latest 3 readings for Other Gross PP&E Adjustments were -$14.0 million in Q4 2025, -$8.2 million in Q3 2025, and -$6.5 million in Q2 2025.